Roche invests $271m in new R&D center in Switzerland

According to the company, the new center, , which is worth CHF250m ($271m), will take the responsibility for investigation and development of pharmaceutical formulations for new active ingredients, english.capital.gr reported citing Dow Jones Newswires.

The facility will also manufacture supplies for global clinical trials.

In addition, methods of processing new active ingredients into tablets, capsules and injectable dosage forms in vials and pre-filled syringes are also believed to be the major activities of the new center.

Roche Group CEO Severin Schwan said their drug development process comprises determining safe formulation for an active ingredient.

"This investment further strengthens the role of Basel headquarters and as a global centre for research and development," Schwan added.